Ian Visit 2 - Worsening Pulmonary Functioning and Follow-Up
| Title: | Ian Visit 2 - Worsening Pulmonary Functioning and Follow-Up |
| Topic: | Pulmonary Disease |
| Relevant Terms: | AATD, COPD, Emphysema, Pulmonary Function |
| Primary Audience: | Internal medicine, Primary Care Physicians, Pulmonologists |
| Launch Date: | 19-Aug-09 |
| Credits: | 0.5 AMA PRA Category 1 Credit™ |
| Expiration Date: | The accreditation for this activity has expired. |
Learning Objectives
After completion of this activity, participants should be better able to:
- Recognize symptoms and comorbidities that may obfuscate a diagnosis of AAT deficiency
- Describe patient selection for augmentation therapy based on the clinical and phenotype characteristics of AAT deficiency
- Discuss initiation and monitoring of augmentation therapy on the basis of ATS/ERS recommendations
Faculty
James K. Stoller, MD, MS
Jean Wall Bennett Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Head, Cleveland Clinic Respiratory Therapy
Chairman, Education Institute
Cleveland Clinic Foundation
Cleveland, Ohio
James M. Stocks, MD, CPI
Professor of Medicine
University of Texas Health Science Center at Tyler
Tyler, Texas
Michael A. Campos, MD
Assistant Professor of Medicine
Division of Pulmonary and Critical Care
Miller School of Medicine
University of Miami
Miami, Florida
Jean Wall Bennett Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Head, Cleveland Clinic Respiratory Therapy
Chairman, Education Institute
Cleveland Clinic Foundation
Cleveland, Ohio
James M. Stocks, MD, CPIProfessor of Medicine
University of Texas Health Science Center at Tyler
Tyler, Texas
Michael A. Campos, MDAssistant Professor of Medicine
Division of Pulmonary and Critical Care
Miller School of Medicine
University of Miami
Miami, Florida
DIME Editor
Dana Ravyn, PhD, MPH
Scientific Director
DIME
Chicago, Illinois
Target Audience
The target audience for this activity includes primary care physicians, pulmonologists and other health care professionals interested in AAT deficiency.
Activity Purpose
The purpose of this activity is to enhance knowledge and competence in physicians and other healthcare professionals managing patients with alpha-1 antitrypsin deficiency in order to improve recognition and patient outcomes.
DISCLOSURE ATTESTATION
*DIME requires that all persons who were in a position to control or influence the content of this CME activity disclose all relevant financial relationships with any commercial interest. This information is used to: (1) determine whether a conflict exists, (2) resolve the conflict by initiating a content validation process, and (3) advise learners of this information.
FACULTY DISCLOSURES
Dr. James K. Stoller has consulted for Arriva Pharmaceuticals, CSL Behring, and Talecris Biotherapeutics Inc. He has received honoraria from Baxter International Inc., CSL Behring, Grifols, S.A., and Talecris Biotherapeutics Inc. Dr. Stoller has no off-label, experimental, and investigational uses to disclose.
Dr. James M. Stocks has received research support from Baxter International Inc., CSL Behring, Kamada, and Talecris Biotherapeutics Inc. He has consulted for and received honoraria from Talecris Biotherapeutics Inc. Dr. Stocks has no off-label, experimental, and investigational uses to disclose.
Dr. Michael A. Campos has consulted for CSL Behring and Talecris Biotherapeutics Inc., and has received honoraria from Talecris Biotherapeutics Inc. Dr. Campos has no off-label, experimental, and investigational uses to disclose.
DIME Editor
Dana Ravyn, PhD, MPH, has nothing to disclose.
DISCLOSURE POLICY STATEMENT
This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. DIME requires the speaker to disclose that a product is not labeled for the use under discussion. The provider's documentation of common practices that make the disclosure requirement known to faculty demonstrates compliance with ACCME guidelines.
DISCLAIMER
In accordance with DIME policies regarding financial and off-label disclosure, the learner is advised that this CME activity may contain references to off-label or unapproved uses of drugs or devices. The use of these agents outside currently approved labeling is considered experimental, and participants are advised to consult prescribing information for these products. This CME activity was planned and produced in accordance with ACCME Essential Areas and Policies.
This activity is funded through an educational grant from Talecris Biotherapeutics Inc. The activity content was developed independently by the contributing faculty or editors. The materials included in this activity have undergone peer review by the chairperson(s) or editor(s). All materials are included with the permission of the authors. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
ACCREDITATION STATEMENT
DIME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION
DIME designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 0.5 AMA PRA Category 1 Credits™. Statement of credit will be available to print from your user history page.
COURSE VIEWING REQUIREMENTS
Release Date: August 19, 2009
Expiration Date: August 31, 2010
COMMERCIAL SUPPORT
Funded by an educational grant from Talecris Biotherapeutics Inc.
This continuing medical education activity is sponsored by DIME.
www.DIMedEd.org
Dana Ravyn, PhD, MPH
Scientific Director
DIME
Chicago, Illinois
Target Audience
The target audience for this activity includes primary care physicians, pulmonologists and other health care professionals interested in AAT deficiency.
Activity Purpose
The purpose of this activity is to enhance knowledge and competence in physicians and other healthcare professionals managing patients with alpha-1 antitrypsin deficiency in order to improve recognition and patient outcomes.
DISCLOSURE ATTESTATION
*DIME requires that all persons who were in a position to control or influence the content of this CME activity disclose all relevant financial relationships with any commercial interest. This information is used to: (1) determine whether a conflict exists, (2) resolve the conflict by initiating a content validation process, and (3) advise learners of this information.
FACULTY DISCLOSURES
Dr. James K. Stoller has consulted for Arriva Pharmaceuticals, CSL Behring, and Talecris Biotherapeutics Inc. He has received honoraria from Baxter International Inc., CSL Behring, Grifols, S.A., and Talecris Biotherapeutics Inc. Dr. Stoller has no off-label, experimental, and investigational uses to disclose.
Dr. James M. Stocks has received research support from Baxter International Inc., CSL Behring, Kamada, and Talecris Biotherapeutics Inc. He has consulted for and received honoraria from Talecris Biotherapeutics Inc. Dr. Stocks has no off-label, experimental, and investigational uses to disclose.
Dr. Michael A. Campos has consulted for CSL Behring and Talecris Biotherapeutics Inc., and has received honoraria from Talecris Biotherapeutics Inc. Dr. Campos has no off-label, experimental, and investigational uses to disclose.
DIME Editor
Dana Ravyn, PhD, MPH, has nothing to disclose.
DISCLOSURE POLICY STATEMENT
This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. DIME requires the speaker to disclose that a product is not labeled for the use under discussion. The provider's documentation of common practices that make the disclosure requirement known to faculty demonstrates compliance with ACCME guidelines.
DISCLAIMER
In accordance with DIME policies regarding financial and off-label disclosure, the learner is advised that this CME activity may contain references to off-label or unapproved uses of drugs or devices. The use of these agents outside currently approved labeling is considered experimental, and participants are advised to consult prescribing information for these products. This CME activity was planned and produced in accordance with ACCME Essential Areas and Policies.
This activity is funded through an educational grant from Talecris Biotherapeutics Inc. The activity content was developed independently by the contributing faculty or editors. The materials included in this activity have undergone peer review by the chairperson(s) or editor(s). All materials are included with the permission of the authors. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
ACCREDITATION STATEMENT
DIME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION
DIME designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 0.5 AMA PRA Category 1 Credits™. Statement of credit will be available to print from your user history page.
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the posttest and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score 70% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the posttest and evaluation will receive a certificate of participation.
COURSE VIEWING REQUIREMENTS
| PC Internet Explorer (v6 or greater), or Firefox |
MAC Safari |
Release Date: August 19, 2009
Expiration Date: August 31, 2010
COMMERCIAL SUPPORT
Funded by an educational grant from Talecris Biotherapeutics Inc.
This continuing medical education activity is sponsored by DIME.
www.DIMedEd.org
